NCT00942825: Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC) |
|
|
| Completed | 2 | 195 | US | CBP501 + Cisplatin + Pemetrexed, CBP501 + CDDP + Alimta, Cisplatin + Pemetrexed, CDDP + Alimta | CanBas Co. Ltd. | Metastatic Non-squamous Non Small Cell Lung Cancer | 07/13 | 07/13 | | |
NCT04953962: Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer |
|
|
| Completed | 2 | 36 | US | CBP501 (16), CBP501, CBP501 (25), Cisplatin, CDDP, Nivolumab, Opdivo | CanBas Co. Ltd. | Pancreatic Cancer Stage IV | 04/23 | 04/23 | | |
NCT00700336: Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) |
|
|
| Completed | 1/2 | 69 | US | pemetrexed, cisplatin and CBP501, Arm A, pemetrexed and cisplatin, Arm B, pemetrexed, cisplatin and CBP501, dose finding, Phase I part, Dose finding | CanBas Co. Ltd. | Malignant Pleural Mesothelioma, Solid Tumors | 07/12 | 11/12 | | |
